Rational & Objective: Data on outcomes of patients with end-stage renal disease (ESRD) secondary to systemic sclerosis (scleroderma) requiring renal replacement therapy (RRT) is limited. We examined the incidence, prevalence and outcomes of European patients starting RRT for ESRD due to scleroderma.
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Conclusions: Survival in patients with scleroderma from day 91 of on RRT was worse than in other causes of ESRD. Patient survival after transplantation was similar to the control groups.
In this study, patients with scleroderma had higher renal function recovery rates than controls.
Index words: incidence, dialysis, end-stage renal disease, outcomes, scleroderma, kidney transplantation Summary: Scleroderma is a rare chronic connective tissue disease with multi-organ involvement. There is limited published data on the outcomes of patients with end-stage renal disease (ESRD) secondary to scleroderma requiring renal replacement therapy (RRT); i.e. dialysis or kidney transplantation. In this European matched-cohort study we examined the incidence, prevalence and outcomes of 342 patients receiving RRT for ESRD due to scleroderma between 2002-2013. The matched controls had a diagnosis of diabetes mellitus or all other diagnoses except diabetes mellitus or scleroderma. Patients with scleroderma receiving RRT had a higher rate of kidney function recovery than the matched controls, though their overall survival was worse. Transplanted patients with scleroderma showed similar survival to the matched-controls, supporting the practice of kidney transplantation in these patients. However, given that these patients had a relatively high rate of recovery of their kidney function after starting dialysis we recommend a period of observation before kidney transplantation is performed. 3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 INTRODUCTION Systemic sclerosis (also referred to as scleroderma) is a rare chronic connective tissue disease with multi-organ involvement characterized by immune activation, vasculopathy, fibroblast dysfunction and excessive collagen accumulation in the skin and internal organs [1] [2] [3] .
Renal disease in patients with scleroderma, particularly scleroderma renal crisis, result in significant morbidity and mortality [1] . Scleroderma renal crisis typically manifests with an acute onset of accelerated hypertension, rapidly progressive renal failure, frequently accompanied by microangiopathic haemolytic anaemia and thrombocytopenia. Occurring in approximately 3-10% of the scleroderma population, severe renal disease is commonly seen in patients with diffuse rather than limited cutaneous scleroderma [1, 4] . Until the 1970s, scleroderma renal crisis was recognized as the main cause of death in patients with scleroderma, though since the introduction of treatment with ACE inhibitors and reduction of corticosteroid doses the prognosis has substantially improved [4] . Nevertheless, about 25-50% of patients with scleroderma renal crisis will develop end-stage renal disease (ESRD) and the mortality associated with this condition remains high [1, [3] [4] [5] [6] [7] .
There is limited knowledge regarding the prevalence of scleroderma renal crisis requiring renal replacement therapy (RRT) [8] and due to the infrequency of this condition there are a limited number of large multicentre or registry-based studies available [3] [4] [5] [6] [7] [9] [10] [11] . While the outcome of patients with scleroderma on dialysis seems to be uniformly worse than that of patients with other causes of ESRD [7, 11] , the outcomes of kidney transplantation are less clear. It is known that renal function may recover after commencing RRT and there is an ongoing discussion regarding the optimal timing of kidney transplantation in patients with scleroderma [5, 12, 13] .
We analysed the trends in incidence and prevalence of RRT for ESRD due to scleroderma in the European Renal Association -European Dialysis and Transplant Association (ERA-1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 EDTA) Registry and determined the patient characteristics, patient survival on RRT, patient and graft survival after kidney transplantation and causes of death in a large cohort of European patients initiating RRT between 2002 and 2013.
METHODS

Patients and data collection
The ERA-EDTA Registry collects data annually on patients starting RRT from national and regional renal registries in Europe. Renal registries sending individual patient level data to the ERA-EDTA Registry between 2002 and 2013, with at least 50% percent coverage of the general population were included in the study. The renal registries included were Austria, Dutch-speaking Belgium, French-speaking Belgium, Denmark, Finland, Greece, Iceland, the Netherlands, Norway, the Spanish regional renal registries of Andalusia, Aragon, Asturias, Basque Country, Cantabria, Castile and León, Catalonia, and Valencia, Sweden, United Kingdom: England, Northern Ireland and Wales, and United Kingdom: Scotland. The details of methods of data collection and data processing are described elsewhere [14] . The cause of death was defined and categorized according to the ERA-EDTA coding system [14] . All national and regional registries contributing data to the ERA-EDTA Registry followed national legislation with regard to ethics committee approval. Additional informed patient consent was not required for this study due to the de-identified nature of the information obtained.
Cases and matched control groups
The incidence, prevalence and patient survival on RRT analyses refer to patients starting RRT for ESRD due to "systemic sclerosis (scleroderma)" (ERA-EDTA primary renal disease
[PRD] code 87 [14] ), as recorded by the responsible physician. Patient and graft survival after 3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 kidney transplantation refer to all patients with a diagnosis of scleroderma, or the matched controls (described below) who received their first kidney-only transplant between 1 st January 2002 and 31 st December 2013. This included patients who commenced RRT for ESRD before 2002. Age and sex were compared between scleroderma and non-scleroderma patients. We then formed two matched control groups of patients without scleroderma: 1) diabetes mellitus as a primary renal disease (PRD codes 80 and 81); and 2) patients without scleroderma and without diabetes mellitus ("non-diabetes") as a primary renal disease. Due to the low number of scleroderma patients, we matched 10 controls to 1 case. We matched on age group at the start of RRT (5-year age groups) and sex, when comparing patients receiving RRT. When comparing transplant recipients we matched on age group at the time of kidney transplantation (5-year age groups) and sex.
Statistical analysis
Time trends in the incidence of RRT per million population (pmp) were studied by year according to the date of RRT onset for all participating European countries/regions combined. regression analysis. Joinpoint regression allows the identification of points in time where a significant change in the linear slope of a trend occurs. The analysis starts with zero joinpoints (i.e. a straight line) and then tests whether one or more joinpoints are significantly different and must be added to the model [16] . This was performed using the Joinpoint software (version 4.0.4) [17] .
To compare the characteristics of scleroderma patients receiving RRT with each of the matched control groups separately, the Wilcoxon signed-rank test was used for continuous variables with a skewed distribution, and the McNemar square test for categorical variables.
A two-tailed p-value <0.05 was considered as statistically significant. The first treatment modality was defined as treatment at day 91 after the start of RRT, as some patients received haemodialysis (HD) for a short period, while preparations were made for peritoneal dialysis (PD).
The Kaplan-Meier method and Cox regression analysis were used for the survival analyses. 3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 the event studied was death, and in case of graft survival, the events were graft failure and death. Reasons for censoring were loss to follow-up and the end of follow-up period (31 st December 2013). In the Cox regression analysis, patient and graft survival were adjusted for time period (as described above), country and donor type.
All analyses were performed using SAS 9.3.
RESULTS
Incidence and prevalence
A total of 342 patients with scleroderma were identified; comprising 0.14% of 236,082 patients starting RRT between 2002 and 2013.
The adjusted incidence of RRT for ESRD due to scleroderma between 2002 and 2013 was 0.18 pmp, ranging from 0.0 to 0.25 pmp between regions/countries ( Table 1 ). The adjusted incidence of RRT for ESRD due to scleroderma was 0.26 pmp in 2002 and 0.12 pmp in 2013 ( Table 2) . There was a trend towards a decline in the incidence pmp over time but this did not reach statistical significance (MPAC = -3.6; [95%CI: -7.9; 0.8]).
During the study period, the adjusted prevalence of RRT for ESRD due to scleroderma varied between 0.73 and 0.95 pmp per year ( Table 2 ) with a statistically significant increase in the prevalence pmp (MPAC = 2.0; [95%CI: 1.0; 2.9]).
Patient characteristics
Patients commencing RRT for ESRD due to scleroderma were significantly younger than 3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 Baseline The group characteristics for the first 90 days or beyond the first 90 days are displayed in Table 3 for patients initiating RRT for ESRD due to scleroderma and for the control groups, matched on age group and sex. The treatment modality at day 91 after the start of RRT was different in patients with scleroderma compared with the matched control groups, with a higher percentage of HD in the scleroderma patients ( Table 3 ; P≤0.01 for both comparisons).
A higher number of deaths during the first 90 days on RRT was observed in the scleroderma patients compared with both matched control groups (12.6% vs. 3.9% and 4.0%, respectively, Table 3 ; P<0.001 for both comparisons).
The percentage of patients who achieved dialysis independency during the first 90 days on RRT did not differ between the scleroderma patients and the matched control groups.
However, a higher proportion of patients with scleroderma recovered renal function beyond this time period (7.6% vs. 0.7% and 2.0% in the matched control groups diabetes and nondiabetes, respectively; both P<0.001). In patients who recovered renal function, the time to recovery was longer in those with a diagnosis of scleroderma than in both matched control groups (median 255. 5 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 was 18.7% for the control group diabetes mellitus and 27.1% for the control group nondiabetes mellitus (both p<0.001 in comparison with scleroderma patients). Figure 1a 1.69-2.39], respectively; Figure 2a ). 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64 The risk of death for patients with scleroderma after kidney transplantation, adjusted for country, time period and donor type, did not differ from patients with diabetes or non-diabetes ( Figure 2b) . Similarly, graft survival adjusted for country, time period and donor type did not differ between the patients with scleroderma and the matched control groups (Figure 2c ). Table 4 shows the causes of death for patients who started RRT for ESRD due to scleroderma and for the matched control groups since day 91. Patients with scleroderma had fewer deaths due to cardiovascular events (particularly myocardial ischemia and cardiac arrest) compared with the matched control group of patients with diabetes. Compared with the matched control group of patients with non-diabetes, there were fewer deaths due to malignancy and cardiac arrest among the patients with scleroderma. Conversely, there were more deaths due to heart failure. A large proportion of deaths in the patients with scleroderma were reported as "miscellaneous" or unknown.
Patient survival on RRT
Patient and graft survival after kidney transplantation
Causes of death
DISCUSSION
Systemic sclerosis is a very rare cause of ESRD, and as such analysis of this condition requires multi-centre, multi-national studies performed over a long period of time. This study describes the characteristics and outcomes of patients with scleroderma requiring RRT in a large European cohort. We found that the age and sex adjusted incidence of RRT for ESRD due to scleroderma between 2002 and 2013 was only 0.18 pmp. There was a trend towards a decline in the incidence over time but this did not reach statistical significance. Conversely   1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 the prevalence significantly increased over the time period from 0.80 pmp in 2002 to 0.89 pmp in 2013. Furthermore, we observed that survival on RRT in patients with scleroderma was worse than in other causes of ESRD, whilst transplant recipients with scleroderma showed a similar survival to the control groups.
Scleroderma is a rare disease with an estimated annual incidence of 10-20 pmp and a prevalence of about 30-300 pmp. The occurrence of scleroderma is presumed to be higher in North America or Australia than in Europe or Asia, even though epidemiological studies are difficult to perform due to the low incidence and heterogeneity of the disease [18, 19] . The overall prevalence of scleroderma in the general population has been reported to increase, probably due to a greater awareness of the disease and improved patient survival [20] , whereas there is in more recent studies some evidence suggesting a lower incidence of scleroderma renal crisis [1] . In keeping with this observation, we observed a non-statistically significant trend towards a decline in the incidence of RRT for ESRD due to scleroderma over time. However, as frequently seen in rare diseases with low numbers of patients, the number of cases in each year fluctuated. In Australia and New Zealand the incidence of patients with scleroderma requiring RRT for ESRD declined significantly between 2002 and 2013, from 0.51 pmp to 0.18 pmp [21] . The prevalence of RRT for ESRD caused by scleroderma increased during the study period. This is most likely explained by the improved survival of patients with scleroderma receiving RRT.
In this study, patients with scleroderma were less likely to be treated with PD than haemodialysis when compared with the matched control groups. This is in contrast to the data from the Australian and New Zealand registry where the use of PD was more common in patients with scleroderma than in patients with other causes of ESRD. However, PD is also a more frequent treatment option for ESRD in Australia than in Europe [11] . The choice of the   1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 "optimal" modality of RRT in patients with scleroderma is generally considered problematic [22] .
Scleroderma has long been recognized as a condition with a relatively high probability of renal recovery, even in patients requiring long-term dialysis [23] . This has important implications regarding the timing of kidney transplantation and some authors have recommended treating patients initially with dialysis for up to two years [13] , whereas, for instance, the Canadian guidelines suggest that kidney transplantation could be considered in patients with scleroderma who have had quiescent disease for at least six months off cytotoxic agents and have limited extra-renal disease [12] . Previous reports have described renal recovery in patients with scleroderma to be as high as 38% [1, 6] . However the Australian and New Zealand Registry, which includes patients with presumed ESRD [11] , reported renal recovery at 10%, which is similar to the 7.6% observed in our study. The proportion of patients with presumed ESRD who recovered renal function in this study was higher in patients with ESRD secondary to scleroderma than in patients with other causes of ESRD. It has been previously noted that systemic autoimmune diseases commonly show higher recovery rates than other PRDs [24, 25]. Importantly, 25% of patients who recovered renal function in the current study discontinued dialysis after more than 15 months of RRT, supporting the recommendation of delaying kidney transplantation in these patients. This may explain why the time spent on dialysis before transplantation was longer in patients with scleroderma than in the matched control groups in our study.
In previous studies exploring the survival of patients with scleroderma receiving RRT, a diagnosis of scleroderma mostly showed unfavourable outcomes [7, 11, 25] and was even identified as an independent predictor of death (HR of 2.47) [11] . Similarly, in the present study, we confirmed that both early and long-term mortality of patients with scleroderma receiving RRT remains high, and that the prognosis is worse than that of RRT patients with 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 diabetes. Among the causes of death, cardiovascular events, especially ischemic heart disease, were much less common in patients with scleroderma than in patients with diabetes.
Nevertheless, detailed evaluation of the causes of death was limited due to the high number of unknown or miscellaneous causes reported in the patients with scleroderma.
Interestingly, patient and graft survival after kidney transplantation did not differ between patients with scleroderma and other PRDs. Given the poorer survival outcomes in patients We are aware of the potential limitations of this study that include the registry-based nature of the data with a lack of detailed information regarding the disease course of individual patients, for example, disease duration prior to RRT, renal biopsy results, extent of extra-renal involvement, administered treatment, or disease recurrence after kidney transplantation. As such there are known and unknown factors which we cannot take into account within this study. It is known that ESRD in some patients with scleroderma is not necessarily caused solely by scleroderma renal crisis, they may have for example normotensive renal crisis, 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 penicillamine-associated nephropathy, scleroderma-associated vasculopathy, a mixed disease and overlap with for example, ANCA-associated vasculitis, in which case their renal survival and renal outcomes may be different [1, 28] . However, we were not able to distinguish such mixed causes of ESRD. Furthermore, on occasion it may be difficult to differentiate between acute cases of kidney failure requiring short-term (but prolonged) dialysis from true ESRD in patients with a diagnosis of scleroderma. The view regarding such patients may differ between registries, some of which may not enter patients who recovered renal function as ESRD into the database, even though the time on dialysis exceeded three months which is typically the cut-off point for entering a patient requiring long-term RRT into the ESRD registry. In addition we do not have access to comorbidity data including diabetic status (beyond diabetes mellitus as a cause of ESRD). Having data on patient co-morbidities is required to further differentiate patients, for example, this information could have in part, accounted for the differences in transplantation rates and time to transplantation between patients with a diagnosis of scleroderma and the control groups. Nor do we have data on vascular access. Problems related to vascular access in patients with scleroderma may have contributed to differences in RRT outcomes when compared to control patients, which we are not aware of. On the other hand, the ERA-EDTA Registry provides a unique opportunity to analyse a large cohort of European patients with scleroderma receiving RRT and also allows for the direct comparison of patients with scleroderma with other causes of ESRD.
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